Sana Biotechnology's (SANA) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA - Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. JMP Securities cut shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. Citigroup raised their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, August 9th.

Sana Biotechnology Stock Up 3.7 %

Shares of Sana Biotechnology stock traded up $0.09 during trading on Wednesday, reaching $2.54. 580,861 shares of the stock were exchanged, compared to its average volume of 2,130,854. Sana Biotechnology has a 1 year low of $2.29 and a 1 year high of $12.00. The firm has a market cap of $567.11 million, a price-to-earnings ratio of -1.75 and a beta of 1.44. The stock's fifty day moving average is $3.65 and its 200 day moving average is $5.24.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. Equities analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now directly owns 2,848,121 shares of the company's stock, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 31.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in Sana Biotechnology in the 3rd quarter worth about $29,000. Barclays PLC raised its holdings in shares of Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company's stock valued at $1,325,000 after purchasing an additional 178,179 shares during the last quarter. Geode Capital Management LLC lifted its position in Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock valued at $13,175,000 after purchasing an additional 276,055 shares during the period. EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology in the third quarter worth approximately $45,000. Finally, State Street Corp raised its stake in Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company's stock valued at $27,570,000 after buying an additional 269,274 shares during the last quarter. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.